CNBC March 26, 2024
Key Points
– Moderna said a new version of its Covid vaccine triggered a stronger immune response against the virus than its current shot on the market in a late-stage trial.
– The results come as Moderna competes with rival Pfizer for more share of the Covid vaccine market and tries to diversify its revenue streams after the steep drop in demand for Covid products last year.
– The biotech company’s new “next-generation” shot offers the potential of a longer shelf life and is one component of its combination vaccine targeting Covid and the flu.
Moderna on Tuesday said a new version of its Covid vaccine triggered a stronger immune response against the virus than its current shot in...
Today's Sponsors
Today's Sponsor